sofosbuvir
Selected indexed studies
- Sofosbuvir: A comprehensive profile. (Profiles Drug Subst Excip Relat Methodol, 2025) [PMID:39855774]
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. (J Antimicrob Chemother, 2021) [PMID:33063117]
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. (Expert Rev Gastroenterol Hepatol, 2021) [PMID:34338120]
_Worker-drafted node — pending editorial review._
Connections
sofosbuvir is a side effect of
Sources
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. (2021) pubmed
- Sofosbuvir: A comprehensive profile. (2025) pubmed
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. (2021) pubmed
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. (2018) pubmed
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. (2018) pubmed
- Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis. (2022) pubmed
- Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. (2016) pubmed
- Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. (2018) pubmed
- Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. (2017) pubmed
- Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment? (2020) pubmed